BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Elacytarabine: Phase III amended

Clavis amended the open-label, international Phase III CLAVELA trial to increase the statistical power of the study to about 90% from 80% in order to increase the chances of success. The changes include increasing enrollment to 400 patients from...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >